ISIS News Alert Isis Pharmaceuticals (ISIS) 59.49 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Isis Pharmaceuticals (ISIS) 59.49 $ISIS

Isis Pharmaceuticals (ISIS) Showing Signs Of A Dead Cat Bounce Today
at The Street - Wed Dec 24, 8:56AM CST
Trade-Ideas LLC identified Isis Pharmaceuticals (ISIS) as a "dead cat bounce" (down big yesterday but up big today) candidate
ISIS: 59.49 (+1.88)

Jim Cramer's Picks for What to Buy in Oil and Biotech Into 2015
at The Street - Wed Dec 24, 7:45AM CST
Here's the best way to play oil and biotech.
CI: 104.23 (-0.08), ESRX: 85.48 (-0.40), RDS.A: 68.42 (-0.31), ISIS: 59.49 (+1.88), COG: 30.21 (-0.39), UNH: 102.68 (-0.17), EOG: 94.05 (-2.36), SLB: 87.06 (-0.26), EPD: 35.45 (+0.25), CELG: 109.60 (+3.48)

After Yesterday's Decline of 8.38%, Isis Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Tue Dec 23, 4:01PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $55.65 to a high of $62.14. Yesterday, the shares fell 8.4%, which took the trading range below the 3-day low of $57.95 on volume of 6.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ISIS: 59.49 (+1.88)

Nasdaq stocks posting largest percentage decreases
AP - Tue Dec 23, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
MCBK: 20.30 (+1.04), ISIS: 59.49 (+1.88), ALNY: 93.52 (+0.97), GILD: 91.29 (+1.84), ASPS: 33.81 (+4.37), ACHN: 13.06 (+1.22), OFLX: 34.45 (unch), RCPT: 122.05 (+4.05), HGSH: 4.60 (-0.06), REXX: 5.17 (-0.17)

Isis Pharmaceuticals Up 84.2% Since SmarTrend Uptrend Call (ISIS)
Comtex SmarTrend(R) - Tue Dec 23, 9:37AM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 5 months, Isis Pharmaceuticals has returned 84.21% as of today's recent price of $61.02.
ISIS: 59.49 (+1.88)

Isis Pharmaceuticals (ISIS) Stock: Weak On High Volume Today
at The Street - Tue Dec 23, 9:04AM CST
Trade-Ideas LLC identified Isis Pharmaceuticals (ISIS) as a weak on high relative volume candidate
ISIS: 59.49 (+1.88)

3 Drugmakers Facing a Pivotal 2015
George Budwell, The Motley Fool - Motley Fool - Mon Dec 22, 10:41AM CST
Source: www.bio.org Pharmaceutical companies have been some of the best performing stocks lately due to the confluence of an aging U.S. population and new regulatory avenues within the Food and Drug Administration that have led to an uptick in drug...
BIIB: 340.89 (+5.13), ISIS: 59.49 (+1.88), GWPH: 68.08 (+1.82), AZN: 70.44 (+0.26), IBB: 299.80 (+5.12), PTCT: 51.66 (+0.76), GSK: 42.85 (+0.11)

Watch for Isis Pharmaceuticals to Potentially Pullback After Gaining 9.30% Yesterday
Comtex SmarTrend(R) - Fri Dec 19, 3:36PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $60.85 to a high of $67.12. Yesterday, the shares gained 9.3%, which took the trading range above the 3-day high of $60.04 on volume of 9.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ISIS: 59.49 (+1.88)

Cramer: ‘Downside’ to Biotech as ImmunoGen Stock Cut in Half
at The Street - Fri Dec 19, 9:46AM CST
TheStreet's Jim Cramer takes a look at Celgene's positive news, as well as the bad news that caused shares of ImmunoGen to be nearly cut in half.
BIIB: 340.89 (+5.13), ISIS: 59.49 (+1.88), GILD: 91.29 (+1.84), IMGN: 5.90 (+0.13), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 8:11AM CST

KMX: 67.61 (-0.15), MOLG: 2.92 (+0.03), CERS: 6.49 (+0.29), OREX: 5.98 (+0.01), APP: 1.06 (+0.01), ISIS: 59.49 (+1.88), PIR: 15.33 (-0.11), BBRY: 10.67 (-0.13), IMGN: 5.90 (+0.13), FMD: 5.06 (unch), RHT: 70.92 (+0.47), PETX: 17.05 (+0.42), NVGN: 2.40 (-0.09), TRXC: 2.79 (+0.03), NQ: 4.32 (-0.36), FINL: 22.79 (+0.17), TNK: 4.74 (+0.04)

Why Isis Pharmaceuticals (ISIS) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 8:00AM CST
Isis Pharmaceuticals has been witnessing a positive trend in its current quarter earnings estimate and possess a favorable Zacks Industry Rank
ISIS: 59.49 (+1.88)

Jim Cramer's Top Stock Picks: BA MMM ISIS Q
at The Street - Fri Dec 19, 5:00AM CST
Cramer says Isis Pharmaceuticals is the next hot biotech and he's a big fan of drug testing provider Quintiles.
MMM: 166.96 (+0.09), Q: 59.48 (+0.01), ISIS: 59.49 (+1.88), BA: 131.24 (+1.21)

Cramer's Mad Money - Which Biotech Is The Next Regeneron? (12/18/14)
SA Editor Miriam Metzinger - Seeking Alpha - Fri Dec 19, 4:45AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday December 18. Recipe For a Rally: Rite Aid (NYSE: RAD ), Kraft (NASDAQ: KRFT ), Accenture (NYSE: ACN ), Darden (NYSE: DRI ), Boeing (NYSE: BA ), 3M (NYSE:...
MMM: 166.96 (+0.09), ISIS: 59.49 (+1.88), Q: 59.48 (+0.01), JBL: 21.88 (+0.17), WYNN: 150.90 (-0.79), KRFT: 63.90 (-0.11), MGM: 20.77 (-0.17), BA: 131.24 (+1.21), ACN: 91.32 (-0.10), REGN: 400.12 (+6.07), DRI: 58.42 (-0.09), RAD: 7.26 (-0.09)

Jim Cramer's 'Mad Money' Recap: 10 Reasons We'll Have a Santa Claus Rally
at The Street - Thu Dec 18, 7:10PM CST
Cramer lists 10 ingredients in this seasonally strong market that will lead to a rally.
WFM: 48.67 (-0.40), MMM: 166.96 (+0.09), WMT: 86.43 (-0.23), HSBC: 47.71 (+0.18), M: 64.26 (+0.22), BA: 131.24 (+1.21), CELG: 109.60 (+3.48), SBUX: 81.27 (-0.16), RIG: 18.77 (-0.37), ISIS: 59.49 (+1.88), JPM: 62.48 (unch), Q: 59.48 (+0.01), GILD: 91.29 (+1.84), KBR: 17.00 (-0.13), FLR: 60.30 (-0.26), COST: 143.65 (-0.50), REGN: 400.12 (+6.07)

Uptrend Call Working As Isis Pharmaceuticals Stock Rises 66.0% (ISIS)
Comtex SmarTrend(R) - Tue Dec 16, 9:07AM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 4 months, Isis Pharmaceuticals has returned 65.97% as of today's recent price of $54.98.
ISIS: 59.49 (+1.88)

Isis Pharmaceuticals Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients With Myotonic Dystrophy Type 1
PR Newswire - Tue Dec 16, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a study for ISIS-DMPKRx in patients with Myotonic Dystrophy Type 1 (DM1). DM1 is a rare genetic neuromuscular disease caused by the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells. ISIS-DMPKRx is specifically designed to reduce toxic DMPK RNA.
ISIS: 59.49 (+1.88)

Trade-Ideas: Isis Pharmaceuticals (ISIS) Is Today's "Water-Logged And Getting Wetter" Stock
at The Street - Mon Dec 15, 10:41AM CST
Trade-Ideas LLC identified Isis Pharmaceuticals (ISIS) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ISIS: 59.49 (+1.88)

Cramer's Mad Money - 13 Things To Watch In The Week Ahead (12/12/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Sun Dec 14, 5:42AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday December 12. 13 Things to Watch in the Week Ahead: Honeywell (NYSE: HON ), Verifone (NYSE: PAY ), Darden (NYSE: DRI ), 3M (NYSE: MMM ), FedEX (NYSE: FDX ),...
JOY: 48.23 (+0.31), FDX: 176.42 (-0.52), MMM: 166.96 (+0.09), LBRDA: 50.88 (-0.37), NKE: 96.29 (+0.32), HON: 101.96 (-0.02), BBRY: 10.67 (-0.13), CHTR: 167.46 (-0.31), XON: 26.19 (+0.67), RMTI: 8.41 (-0.07), ORCL: 46.23 (+0.22), DRI: 58.42 (-0.09), KMX: 67.61 (-0.15), PAYX: 47.06 (-0.31), ISIS: 59.49 (+1.88), RHT: 70.92 (+0.47), JDSU: 14.01 (+0.13), AGIO: 109.67 (+2.45), FL: 55.31 (+0.09), PAY: 37.55 (-0.83), REGN: 400.12 (+6.07), PII: 150.40 (+0.38)

Venous Thromboembolism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/h48x9c/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Bayer AG - Portola Pharmaceuticals, Inc. - Green Cross Corporation - Regado Biosciences, Inc. - GlycoMimetics, Inc. - Gamma Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/h48x9c/venous
PTLA: 28.35 (+0.21), ISIS: 59.49 (+1.88), GLYC: 7.81 (-0.42), RGDO: 0.89 (unch)

Jim Cramer's Top Stock Picks: RH COST AGIO BLUE ISIS
at The Street - Thu Dec 11, 5:00AM CST
Restoration Hardware and Costco should benefit from lower oil prices, and the recent drop in Agios' and Bluebird Bio's shares means a buying opportunity, Cramer says.
BLUE: 88.76 (+3.23), RH: 96.97 (-0.16), ISIS: 59.49 (+1.88), COST: 143.65 (-0.50), AGIO: 109.67 (+2.45)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 113

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 107

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 100

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 121

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading

Top 5 Most Recently Viewed Articles

ICG Enterprise Trust plc Announces Share Repurchase Details

Updated Category News Views 159

ICG Enterprise Trust plc Share Buyback Announcement ICG Enterprise Trust plc (the “Company”) The Company has announced a recent development regarding its share buyback initiative. On a significant date, it repurchased 15,000 of its own shares aimed to be held as treasury shares, with each share valued at an average price of 1450 pence. Details of the Transaction...

Continue Reading
Converge Technology Solutions Shares Third Quarter 2024 Insights

Updated Category News Views 217

Converge Technology Solutions Announces Preliminary Q3 Results Converge Technology Solutions Corp. (CTS) has released its preliminary unaudited financial results for the third quarter of 2024. The company is committed to delivering insightful updates to its stakeholders as part of its transparency approach. The company stated that all figures are presented in Canadian...

Continue Reading
Discovery Silver Corp. Unveils 2023 ESG Report

Updated Category News Views 104

Discovery Silver Corp. Releases 2023 ESG Report Key Highlights: Earned Quality Environmental Certification from the Mexican Government Recognized as a Socially Responsible Enterprise by the Mexican Center for Philanthropy Achieved Great Place to Work Certification Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) is excited to announce the publication of its 2023...

Continue Reading
Final Call for Subscription in IDEX Biometrics Offering Today

Updated Category News Views 152

Important Subscription Period Details for IDEX Biometrics Today marks a significant turning point for IDEX Biometrics ASA as the subscription period for their subsequent offering of shares closes. The company previously announced that they aim to issue up to 600 million new shares at a remarkable subscription price of NOK 0.01 per share. This offering, essential for...

Continue Reading
Dundee Corporation Strengthens Position in Greenheart Gold Inc.

Updated Category News Views 33

Overview of Recent Acquisition Dundee Corporation (TSX: DC.A) has announced that its wholly-owned subsidiary, Dundee Resources Limited, recently acquired 2,000,000 common shares of Greenheart Gold Inc. (TSXV: GHRT) at a price of C$0.50 per share, totaling an investment of C$1,000,000. This acquisition is part of the Issuer's bought deal private placement and signifies...

Continue Reading